Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.

Haderski GJ, Kandar BM, Brackett CM, Toshkov IM, Johnson CP, Paszkiewicz GM, Natarajan V, Gleiberman AS, Gudkov AV, Burdelya LG.

PLoS One. 2020 Feb 6;15(2):e0227940. doi: 10.1371/journal.pone.0227940. eCollection 2020.

2.

Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation.

Toshkov IA, Gleiberman AS, Mett VL, Hutson AD, Singh AK, Gudkov AV, Burdelya LG.

Radiat Res. 2017 May;187(5):570-580. doi: 10.1667/RR14514.1. Epub 2017 Mar 21.

3.

Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.

Brackett CM, Kojouharov B, Veith J, Greene KF, Burdelya LG, Gollnick SO, Abrams SI, Gudkov AV.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E874-83. doi: 10.1073/pnas.1521359113. Epub 2016 Feb 1.

4.

The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.

Yang H, Brackett CM, Morales-Tirado VM, Li Z, Zhang Q, Wilson MW, Benjamin C, Harris W, Waller EK, Gudkov AV, Burdelya LG, Grossniklaus HE.

Oncotarget. 2016 Jan 19;7(3):2936-50. doi: 10.18632/oncotarget.6500.

5.

Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice.

Kojouharov BM, Brackett CM, Veith JM, Johnson CP, Gitlin II, Toshkov IA, Gleiberman AS, Gudkov AV, Burdelya LG.

Oncotarget. 2014 Feb 15;5(3):802-14.

6.

A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity.

Leigh ND, Bian G, Ding X, Liu H, Aygun-Sunar S, Burdelya LG, Gudkov AV, Cao X.

PLoS One. 2014 Jan 14;9(1):e85587. doi: 10.1371/journal.pone.0085587. eCollection 2014.

7.

Combined stimulation of Toll-like receptor 5 and NOD1 strongly potentiates activity of NF-κB, resulting in enhanced innate immune reactions and resistance to Salmonella enterica serovar Typhimurium infection.

Tukhvatulin AI, Gitlin II, Shcheblyakov DV, Artemicheva NM, Burdelya LG, Shmarov MM, Naroditsky BS, Gudkov AV, Gintsburg AL, Logunov DY.

Infect Immun. 2013 Oct;81(10):3855-64. doi: 10.1128/IAI.00525-13. Epub 2013 Jul 29.

8.

Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist.

Burdelya LG, Brackett CM, Kojouharov B, Gitlin II, Leonova KI, Gleiberman AS, Aygun-Sunar S, Veith J, Johnson C, Haderski GJ, Stanhope-Baker P, Allamaneni S, Skitzki J, Zeng M, Martsen E, Medvedev A, Scheblyakov D, Artemicheva NM, Logunov DY, Gintsburg AL, Naroditsky BS, Makarov SS, Gudkov AV.

Proc Natl Acad Sci U S A. 2013 May 14;110(20):E1857-66. doi: 10.1073/pnas.1222805110. Epub 2013 Apr 29.

9.

A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease.

Ding X, Bian G, Leigh ND, Qiu J, McCarthy PL, Liu H, Aygun-Sunar S, Burdelya LG, Gudkov AV, Cao X.

J Immunol. 2012 Nov 15;189(10):4719-27. doi: 10.4049/jimmunol.1201206. Epub 2012 Oct 8.

10.

Hypoxia suppresses conversion from proliferative arrest to cellular senescence.

Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV.

Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13314-8. doi: 10.1073/pnas.1205690109. Epub 2012 Jul 30.

11.

Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy.

Burdelya LG, Gleiberman AS, Toshkov I, Aygun-Sunar S, Bapardekar M, Manderscheid-Kern P, Bellnier D, Krivokrysenko VI, Feinstein E, Gudkov AV.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):228-34. doi: 10.1016/j.ijrobp.2011.05.055. Epub 2011 Oct 14.

12.

A In Vitro and In Vivo Study of the Ability of NOD1 Ligands to Activate the Transcriptional Factor NF-kB.

Tukhvatulin AI, Logunov DY, Gitlin II, Shmarov MM, Kudan PV, Adzhieva CA, Moroz AF, Kostyukova NN, Burdelya LG, Naroditsky BS, Gintsburg AL, Gudkov AV.

Acta Naturae. 2011 Jan;3(1):77-84.

13.

Mycoplasma infection suppresses p53, activates NF-kappaB and cooperates with oncogenic Ras in rodent fibroblast transformation.

Logunov DY, Scheblyakov DV, Zubkova OV, Shmarov MM, Rakovskaya IV, Gurova KV, Tararova ND, Burdelya LG, Naroditsky BS, Ginzburg AL, Gudkov AV.

Oncogene. 2008 Jul 31;27(33):4521-31. doi: 10.1038/onc.2008.103. Epub 2008 Apr 14.

14.

An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models.

Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, Kurnasov OV, Fort FL, Osterman AL, Didonato JA, Feinstein E, Gudkov AV.

Science. 2008 Apr 11;320(5873):226-30. doi: 10.1126/science.1154986.

15.

Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice.

Burdelya LG, Komarova EA, Hill JE, Browder T, Tararova ND, Mavrakis L, DiCorleto PE, Folkman J, Gudkov AV.

Cancer Res. 2006 Oct 1;66(19):9356-61.

16.

Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation.

Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R, Komarova EA, Gudkov AV.

Nat Chem Biol. 2006 Sep;2(9):474-9. Epub 2006 Jul 23.

PMID:
16862141
17.

Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors.

Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR, Gudkov AV.

Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17448-53. Epub 2005 Nov 15.

18.

Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells.

Lu T, Burdelya LG, Swiatkowski SM, Boiko AD, Howe PH, Stark GR, Gudkov AV.

Proc Natl Acad Sci U S A. 2004 May 4;101(18):7112-7. Epub 2004 Apr 26.

19.

Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.

Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, Chumakov PM, Cohen MB, Gudkov AV.

Cancer Res. 2003 Jun 1;63(11):2905-12.

20.

Bing de ling, a Chinese herbal formula, stimulates multifaceted immunologic responses in mice.

Niu G, Tan J, Turner JG, Brabham JG, Burdelya LG, Crucian BE, Wall-Apelt H, Zhao RJ, Yu H.

DNA Cell Biol. 2000 Aug;19(8):515-20.

PMID:
10975469
21.
22.

Antioxidant defence mechanisms and PGE secretion by different types of transformed and tumor cells: in vivo selective advantages.

Deichman GI, Kashkina LM, Kluchareva TE, Matveeva VA, Uvarova EN, Burdelya LG.

Adv Exp Med Biol. 1997;400A:473-7. No abstract available.

PMID:
9547592

Supplemental Content

Loading ...
Support Center